Montreux Healthcare Fund

Bellevue Asset Management AG – Are healthcare stocks poised for a comeback?

Retrieved on: 
Thursday, December 21, 2023
Annual report, Post office box, Vertex Pharmaceuticals, Novo Nordisk, Investment, Capital, Intuitive Surgical, Diabetes, CRISPR Therapeutics, Montreux Healthcare Fund, SIX Swiss Exchange, ChatGPT, Acquisition, Artificial intelligence, Health care, Lux, Growth, AI, Grand Canal Dock, Eli Lilly, Economics, Judgement, Risk, University of Zurich, Clinical trial, AG, House, CNMV, Prospectus, Biotechnology, Hematology, Thermo Fisher Scientific, Doctor of Philosophy, DNA, Genome, Roche, History, Therapy, Failure, Health, D, Patient, Obesity, CHF, Medtech, South, TEL, Harmony Row, Research, SICAV, University, Federal Executive Boards, News, DSM-IV codes, Pharmaceutical industry, Medical device, Cryptocurrency, Libre, Amgen

Bellevue Asset Management AG – Are healthcare stocks poised for a comeback?

Key Points: 
  • Bellevue Asset Management AG – Are healthcare stocks poised for a comeback?
  • In his investment outlook for 2024, Cyrill Zimmermann, a member of Bellevue Asset Management’s Executive Board and Head of Healthcare Funds & Mandates, explains why it is probably only a matter of time before healthcare stocks are rediscovered by the wider investment community.
  • In view of this dynamic situation, Bellevue Asset Management launched Bellevue Obesity Solutions in November, a fund that invests in the most attractive companies across the entire value chain for obesity treatment and management.
  • Dr. Cyrill Zimmermann is Head of Healthcare Funds & Mandates and a member of the Executive Board of Bellevue Asset Management.

LifeQ Partners with AAIC Investment to Improve Health Care in Africa and Lead Health Tech Revolution

Retrieved on: 
Monday, November 20, 2023
Montblanc, Motorola, Safety, Android, AAIC, Electronics, Nobuhiko, Insurance, Texas Instruments, Conditional sentence, Health, Montreux Healthcare Fund, Software, Partnership, Apple, Knowledge, Silicon, Pixart, Analog Devices, Physiology, Life, Samsung, Pharmaceutical industry, Mobile phone, Medical imaging, Qualcomm, Suunto

ATLANTA, Nov. 20, 2023 /PRNewswire/ -- LifeQ, the company that uses globally recognized watch brands to generate personalized, clinical-grade health insights, announced its partnership with AAIC Investment, a Singapore-based investment firm focusing on fast-growing companies within the healthcare sector in Africa. LifeQ co-founder Laurence (Laurie) Olivier, CEO, made the announcement.

Key Points: 
  • "LifeQ is proud to partner with AAIC Investment, who are deeply committed to improving healthcare in Africa and catalyzing value transfer between all their stakeholders," stated Mr. Olivier.
  • LifeQ's accessible, real-world healthcare solutions through wearable devices will have a significant positive impact for both consumer and clinical applications across Africa and beyond."
  • Established in 2013, AAIC Investment is the fund management arm of AAIC Holdings.
  • AAIC had already commenced connecting LifeQ with their Japanese stakeholders before their investment was finalized.

Pitango HealthTech Announces the First Closing of Its New Fund, Pitango HealthTech II

Retrieved on: 
Wednesday, September 6, 2023
Drug development, Femtech, Senior, Clinical trial, Special, Woman, Pitango, Magenta, Partner (business rank), Sail components, Investment, Partner, Biology, Artificial intelligence, Montreux Healthcare Fund, ESG, Growth, AI, Environment, Data science, Software, Pharmaceutical industry

HERZLIYA, Israel, Sept. 6, 2023 /PRNewswire/ -- Pitango HealthTech, Pitango VC's dedicated healthcare fund, today announced the first closing of its second dedicated healthcare fund, Pitango HealthTech II. Pitango HealthTech II, a $175M fund, will be dedicated to investing in entrepreneurs leveraging data science, AI, medical devices and novel biology at the forefront of the transformation of healthcare.

Key Points: 
  • HERZLIYA, Israel, Sept. 6, 2023 /PRNewswire/ -- Pitango HealthTech , Pitango VC's dedicated healthcare fund, today announced the first closing of its second dedicated healthcare fund, Pitango HealthTech II.
  • Pitango HealthTech II, a $175M fund, will be dedicated to investing in entrepreneurs leveraging data science, AI, medical devices and novel biology at the forefront of the transformation of healthcare.
  • Pitango HealthTech II invests in healthcare innovation, including the decentralization of healthcare, personalized medicine, medical devices and diagnostics, as well as artificial intelligence, software and data infrastructure.
  • Pitango HealthTech is part of the Pitango investment platform, operating alongside Pitango First and Pitango Growth Funds.

The Sale of Construction Equipment in New Zealand is Expected to Reach 5,113 Units by 2029 - Arizton

Retrieved on: 
Wednesday, July 5, 2023
Volvo Construction Equipment, Kiwi, Education, Waste management, Construction, JCB, Komatsu, Carbon, Government, Hospital, Investment, Lifting, Public Buildings Act, Montreux Healthcare Fund, Demolition, Renewable energy, Caterpillar

The New Zealand market experiences high demand for electric construction equipment.

Key Points: 
  • The New Zealand market experiences high demand for electric construction equipment.
  • Several construction equipment manufacturers, such as Komatsu, Volvo Construction Equipment, and Caterpillar, have recently launched compact electric construction equipment in New Zealand to tackle the growing demand for these tools.
  • Rising green & sustainable building construction in the country is expected to trigger the need for electric construction equipment in New Zealand.
  • Therefore, a rise in investments in infrastructure, including investments in healthcare & public transports, are expected to drive the demand for construction equipment in New Zealand.

BIRCHWOOD HEALTHCARE PARTNERS ACHIEVES MAJOR MILESTONE WITH COMPLETION OF INITIAL CLOSING FOR 5V+ SENIORS HEALTHCARE FUND, TARGETING $100M IN EQUITY AUM

Retrieved on: 
Thursday, June 15, 2023
Government, Montreux Healthcare Fund, Wind, Transition, Acquisition, Senior, Health insurance

CHICAGO, June 15, 2023 /PRNewswire/ -- Birchwood Healthcare Partners, a distinguished player in the American seniors healthcare industry, is delighted to announce a significant milestone: the successful conclusion of initial fundraising for the 5V+ Seniors Healthcare Fund.

Key Points: 
  • CHICAGO, June 15, 2023 /PRNewswire/ -- Birchwood Healthcare Partners, a distinguished player in the American seniors healthcare industry, is delighted to announce a significant milestone: the successful conclusion of initial fundraising for the 5V+ Seniors Healthcare Fund.
  • Birchwood extends its gratitude to the esteemed investors for their confidence in the 5V+ Seniors Healthcare Fund and its sponsorship.
  • The 5V+ Seniors Healthcare Fund provides investors with comprehensive exposure to four key verticals of seniors healthcare: Senior Housing, Healthcare Services, Transitional & Long-Term Care, and Active Adult.
  • For more information about the 5V+ Seniors Healthcare Fund or to explore potential partnerships, please contact our Senior Vice President of Investor Relations, Bill Brennan, at [email protected] .

Biora Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Tuesday, May 10, 2022
COVID-19, ECCO, Private Securities Litigation Reform Act, Ulcerative colitis, Senior, Nasdaq, GLOBE, UC, Result, Comparison, Patient, Trial of the century, Webcast, Serri, Sardinia, Annual report, Analysis, Therapy, Investor relations, Montreux Healthcare Fund, Precision medicine, European, Disease, DDS, Congress, SEC, Financial condition report, Research, Communications satellite, Medical device, Healthcare, Pharmaceutical industry, Online gambling, Video game, Aquaculture, GI, Gastroenterology

SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022.

Key Points: 
  • Management will host conference call and webcast today at 4:30 p.m. Eastern / 1:30 p.m. Pacific
    SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today provided a corporate update andreported financial results for the first quarter ended March31, 2022.
  • The companys launch of Biora Therapeutics is aligned with its mission to reimagine therapeutics and their delivery.
  • We are happy with the progress of the company transformation, which has culminated in the launch of Biora Therapeutics, said Adi Mohanty, Chief Executive Officer of Biora Therapeutics.
  • Biora Therapeutics will host a webcast and conference call to discuss the first quarter financial results and answer investment community questions today, Wednesday, May 10, 2022 at 4:30 p.m. Eastern / 1:30 p.m. Pacific.

Aerium Therapeutics launches to develop novel therapeutics against COVID-19 and future pandemic threats

Retrieved on: 
Tuesday, March 22, 2022
Aerium, Pantaleo, Therapy, Vaccination, DRS, Degenerative disease, Medtech, Leadership, Multimedia, Board, Omega, Health care, Vaccine, Volatile organic compound, EPFL, Research, White, Delta, Capital, Severe acute respiratory syndrome coronavirus 2, Precision medicine, CEO, AstraZeneca, Immunology, Merck & Co., White House, CHUV, Omicron, Technology, Neutralizing antibody, Virology, COVID-19, Trono, Montreux Healthcare Fund, Series, BioRxiv, Bill & Melinda Gates Foundation, FDA, Director, History, Partnership, Antibody, Financial services, Management, Pharmaceutical industry, Medicine, Takeda, Coalition for Epidemic Preparedness Innovations, Pfizer, Ultragenyx, Tropical Islands Resort, Genetics

While we are initially assisting populations vulnerable to COVID-19 in the prophylactic and therapeutic settings, our overall vision is to develop effective therapeutics against not just existing but also future epidemic and pandemic threats."

Key Points: 
  • While we are initially assisting populations vulnerable to COVID-19 in the prophylactic and therapeutic settings, our overall vision is to develop effective therapeutics against not just existing but also future epidemic and pandemic threats."
  • Aerium Therapeutics has assembled a growing team of proven life science and enterprise leaders including:
    CEO Rajeev Venkayya, M.D.
  • Aerium Therapeutics is dedicated to epidemic and pandemic preparedness through the discovery and development of antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats.
  • The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future.

Orange Grove Bio, AlleyCorp and Alexandria Venture Investments Establish Partnership with Albert Einstein College of Medicine to Support Development of Novel Therapeutics

Retrieved on: 
Thursday, October 21, 2021
Science, Program, Albert Einstein College of Medicine, Research, Technology, Acceleration, Silicon Valley Bank, Ecosystem, Cancer, Gilt Groupe, Genomics, Drug development, Partnership, Patient, Montreux Healthcare Fund, Drug discovery, Lists of diseases, NYSE, Investment, Business Insider, Alexandria Real Estate Equities, Synthetic biology, MongoDB, Neuroscience, Silicon, Growth, OGB, Health, University, Therapy, GLOBE, Nomad Health, Translation, Business development, Robotics, Pharmaceutical industry

NEW YORK, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Orange Grove Bio, AlleyCorp and Alexandria Venture Investments, three industry leaders dedicated to the acceleration and growth of innovative healthcare and life science companies, today announced the formation of a partnership program with Albert Einstein College of Medicine to support the development of novel therapeutics. Through the newly established program, Einstein scientists will have the opportunity to receive expert mentorship and financial support to advance their foundational research and streamline translation of their discoveries into new drug candidates.

Key Points: 
  • NEW YORK, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Orange Grove Bio, AlleyCorp and Alexandria Venture Investments, three industry leaders dedicated to the acceleration and growth of innovative healthcare and life science companies, today announced the formation of a partnership program with Albert Einstein College of Medicine to support the development of novel therapeutics.
  • Program participants will be selected by an expert panel of scientists, investors and drug development professionals based on submitted applications.
  • Selected project teams will receive more than six months of director mentorship designed to assist in translating their discoveries into novel therapeutic candidates.
  • Through this new partnership, Orange Grove Bio, AlleyCorp and Alexandria Venture Investments are working to leverage our combined expertise in drug development, company formation and fundraising to support Einstein scientists in translating their groundbreaking discoveries into the impactful treatments of tomorrow.